Drugs Information:
Tafamidis
Basic Information
|
|
||
| ID | DDInter1737 | |
| Drug Type | small molecule | |
| Molecular Formula | C14H7Cl2NO3 | |
| Molecular Weight | 308.116 | |
| CAS Number | 594839-88-0 | |
| Description | Tafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives[A27206] developed by FoldRX.[A189717] Tafamidis is structurally similar to diflusinal.[A189717] Tafamidis was granted an EMA market authorisation on 16 November 2011[L6247] and FDA approval on 3 May 2019.[L11280] | |
| ATC Classification | N07XX08 | |
| IUPAC Name | 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid | |
| InChI | TXEIIPDJKFWEEC-UHFFFAOYSA-N | |
| Canonical SMILES | OC(=O)C1=CC=C2N=C(OC2=C1)C1=CC(Cl)=CC(Cl)=C1 | |
| Useful Links | DrugBank ChEBI PubChem Substance KEGG Drug ChemSpider BindingDB Wikipedia ChEMBL ZINC | |
Interactions with
Tafamidis
Filter:
| Severity level | ID | Name | Mechanism | Detail |
|---|
Interactions with diseases
Filter:
| Severity level | Disease name | Text | References |
|---|
Interactions with foods
Filter:
| Severity level | Food name | Description | Management | Mechanism | References |
|---|
Interactions with compound preparation
| Multi-DRUG trade | Multi-DRUG | Drug type | Warning | Note |
|---|